An emerging ingredient is the maqui berry, with data from humans and lab rats supporting a potential role to help manage blood sugar levels and lower insulin responses.
Scientists from the University Austral in Valdivia, Chile, reported in Panminerva Medica that data from a single dose human study and animal experiments indicated that the Delphinol-branded maqui berry extract lowered blood glucose in humans by inhibiting the sodium glucose co-transporter, which facilitates glucose uptake from food into intestinal tissue and the blood.
“We have discovered a unique mechanism for the dietary supplement Delphinol, which may help control blood glucose also in response to refined sugar consumption,” said Professor Rafael Burgos, corresponding author of the new paper published in Panminerva Medica.
The ingredient is manufactured exclusively by Maqui New Life (MNL), and is for food, beverage, and supplements. Delphinol is standardized to 35% Anthocyanins, and 28% delphinidin.
Hector Bandelier, CEO of MNL Group Switzerland, welcomed the results of the 2014 study, and said: “Delphinol gives formulators the possibility to create complex sugar-control products that are not limited to addressing starchy foods, but to additionally control refined sugars such as sucrose and pure glucose.”